Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 7, 2026CancersOpen Access

The Great Debate: CAR-T-Cell Therapy Versus Bispecific Antibodies in B-Cell Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMassimo MartinoVMVioletta MarafiotiMPMartina Pitea

Discussion

Loading...

Member takes

Overview

Narrative synthesis compares CAR-T therapy and bispecific antibodies for B-cell lymphoma treatment, suggesting tailored approaches.

Key Points

  • This research aims to compare CAR-T-cell therapy and bispecific antibodies for treating relapsed/refractory large B-cell lymphoma.
  • Narrative synthesis of pivotal and updated phase 2 and 3 trial data, real-world evidence, and published meta-analyses.
  • CAR-T therapy shows superior event-free survival compared to standard chemo-transplant regimens in the second-line setting.
  • A meta-analysis indicates higher complete response rates for CAR-T compared with bispecific antibodies.
  • Real-world effectiveness of CAR-T aligns closely with clinical trial outcomes, while bispecific antibodies tend to show lower complete response rates.

Cite This Study

Martino et al. (2026) studied this question.

synapsesocial.com/papers/6a758c01847ab6d26c01fab3https://doi.org/10.3390/cancers18152513
View Full Paper
Ask AI
Bookmark
Share